市场见解

The Healius (ASX:HLS) share price receives a boost

The Healius Ltd (ASX: HLS) share price received a boost in early trade after the company released its first-half report. At the time of writing, the Healius share price was up 4.10% to $4.06. Healius share price gets a boost from results Earlier today, Healius released strong results for the first half of FY21 ending
The post The Healius (ASX:HLS) share price receives a boost appeared first on The Motley Fool Australia. –

Pointing to an upward trend in data on screen.

The Healius Ltd (ASX: HLS) share price received a boost in early trade after the company released its first-half report. At the time of writing, the Healius share price was up 4.10% to $4.06.

Healius share price gets a boost from results

Earlier today, Healius released strong results for the first half of FY21 ending 31 December 2020.

The company’s report was headlined by a 190% increase in net profit after tax (NPAT) of $75.6 million. For the half-year, Healius also reported a 230% increase in earnings before interest and tax (EBIT) of $136.6 million.

For the first 6 months of FY21, Healius generated $953.5 million in underlying revenue. The rebound in revenue marked a 16% increase compared to the $817.4 million generated in the first half of FY20.

Despite a rise in underlying net profits, Healius recorded a lower statutory net profit of $62.8 million. The company also highlighted the sale of its medical and dental centres late last year, with Healius banking $489.2 million.

Healius noted its strong capital position, with the company recording a 56.2% increase in operating cash flow of $251.2 million. In addition, the company declared a fully franked interim dividend of 6.5 cents per share, representing a 55% payout ratio.

Riding COVID-19 revenue wave

Despite the COVID-19 pandemic impacting certain divisions, Healius saw its pathology department perform strongly. For the half-year, the company saw revenue in its pathology division rise 22% to $711.4 million. Healius attributed the strong performance to robust COVID-19 testing volumes.

On the contrary, the company saw government-imposed lockdowns impact its imaging division. As a result, Healius reported a 39.1% decline in EBIT for its imaging department for the half-year.

Healius also noted a 21.5% increase in revenue from its day hospitals division. For the first half, the division reported revenue of $41.8 million and EBIT of $6.8 million.

Healius chief executive, Dr. Malcolm Parmenter, noted that:

The results delivered for 1H 2021 demonstrate the inherent strength of our simplified portfolio and value proposition centred on our specialist diagnostics businesses, while the performance of Day Hospitals validates our confidence in the medium and long-term prospects of this business.

The outlook for Healius

Management noted that Healius is well positioned for the second half of FY21, as non-COVID revenue streams recover across its divisions.

Given the fluid nature of the COVID-19 pandemic, the company’s management did not provide guidance for the full year.

At the time of writing, the Healius share price is trading more than 3% higher for the day.

Where to invest $1,000 right now

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now.

See The 5 Stocks

*Returns as of February 15th 2021

More reading

Motley Fool contributor Nikhil Gangaram has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The post The Healius (ASX:HLS) share price receives a boost appeared first on The Motley Fool Australia.

随时随地,交易世界!

移动APP平台,拥有 12 个市场的 50,000 多种全球上市证券(全球市值超过 70%),直接在您的 Android 或 iOS 设备上即可操作。

与独有的交易理念和投资分析工具相结合,帮助您在我们 12 个全球市场中的几乎所有金融工具上找到可操作的见解,从而帮助您优化交易策略。

推荐给您的朋友

向您的朋友推荐Monex并赠予他们免费使用我们交易工具的机会

我们尊重您的隐私,只会向您的朋友发送一封邮件 

与您的朋友分享

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;


To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.


An active and funded account with a positive trading balance is required to continue to have access to the tools;


Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;


Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!